Sodium valproate inhibits in vivo growth of human neuroblastoma cells

Anti-Cancer Drugs

Volumn 8, Issue 10, 1997, Pages 958-963

  Cinatl Jr , Jindrich ^a   Cinatl, Jaroslav ^a   Hernáiz Driever, Pablo ^a   Kotchetkov, Ruslan ^a   Pouckova, Pavla ^b   Kornhuber, Bernhard ^a   Schwabe, Dirk ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b KLINLAB   (Czech Republic)

Author keywords

Apoptosis; Cell differentiation; Neuroblastoma; Sodium valproate; Xenograft

Indexed keywords

VALPROIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL;

EID: 0031458318     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199711000-00007     Document Type: Article

References (27)

1. Ambros PF, Ambros IM, Strehl S, et al. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour? Eur J Cancer 1995; 4: 510-5.
2. Castle VP, Heidelberg KP, Bromberg J, Ou X, Dole M, Nunez G. Expression of the apoptosis-suppressing protein Bcl-2 in neuroblastoma is associated with poor stage disease, unfavorable histology and N-myc amplification. Am J Pathol 1993; 143: 1543-50.
3. Christiansen H, Delattre O, Fuchs S, et al. Loss of putative tumor suppressor-gene locus 1p36 as investigated by a PCR assay and N-myc amplification in 48 neuroblastomas: results of the German Neuroblastoma Study Group. Progr Clin Biol Res 1994; 385: 19-25.
4. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW. Prognostic factors in neuroblastoma. Cancer 1987; 59: 1853-9.
5. Abemayor E, Chang B, Sidell N. Effects of retinoic acid on the in vivo growth of human neuroblastoma cells. Cancer Lett 1990; 55: 1-5.
6. Cinatl J Jr, Cinatl J, Scholz M, et al. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anti-Cancer Drugs 1996; 7: 766-73.
7. Cinatl J, Cinatl J, Mainke M, et al. In vitro differentiation of human ncuroblastoma cells induced by sodium phenylacetate. Cancer Lett 1993; 70: 15-24.
8. Comaglia-Ferraris P, Mariottini GL, Ponzoni M. γ-Interferon and retinoic acid synergize in inhibiting the growth of human neuroblastoma cells in nude mice. Cancer Lett 1992; 61: 215-20.
9. Miller AA, Kurschel H, Osieka R, Schmidt CG. Clinical Pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987; 23: 1283-7.
10. Parkinson DR, Pluda JM, Cazenave L, et al. Investigational anticancer agents. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy. Philadelphia: Lippincott-Raven 1996: 509-27.
11. Reynolds CP, Kane DJ, Einhorn PA, et al. Response of neuroblastoma to retinoic acid in vitro and in vivo. In: D'Angio GJ, Knudson AG, Evans AE, Seeger RC, eds. Advances in neuroblastoma research 3. New York: Willey-Liss 1991: 203-11.
12. Thibault A, Cooper MR, Figg W, et al. A phase I and pharmacokinetics study of intravenous phenylacetate in patients with cancer. Cancer Res 1994; 54: 1690-4.
13. Samid D, Ram Z, Hudgins WR, et al. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 1994; 54: 891-5.
14. Samid D, Shack S, Sherman LT. Phenylacetate: a novel non-toxic inducer of tumor cell differentiation. Cancer Res 1992; 52: 1988-92.
15. Samid D, Yen A, Prasanna P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 1992; 80: 1576-81.
16. Brusilow SW, Danney M, Waber LJ, et al. Treatment of episodic hyperammonemia in children with errors of urea synthesis. N Engl J Med 1984; 310: 1630-4.
17. Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC. Mechanism of anticonvulsant action of valproate. Progr Neurobiol 1982; 19: 315-59.
18. Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-72.
19. Collins AF, Dover GJ, Luban NLC. Increased fetal hemoglobin production in patients receiving valproic acid for epilepsy. Blood 1994; 84: 1690-1.
20. Knüpfer MM, Hernáiz Driever P, Poppenborg H, et al. Valproic acid inhibits proliferation and changes CD56 and CD44 expression in malignant glioma cells. Klin Päd 1997; in press.
21. Cinatl J Jr, Cinatl J, Mainke M, et al. Aphidicolin selectively kills neuroblastoma cells in vitro. Cancer Lett 1992; 67: 199-206.
22. Cinatl J Jr, Vogel J-U, Cinatl J, et al. Long-term productive human cytomegalovirus infection of a human neuroblastoma cell line. Int J Cancer 1996; 65: 90-6.
23. Houchens DP, Ovejera AA, Barker AD. The therapy of human tumors in athymic (nude) mice. In: Houchens DP, Ovejera AA, eds. Proc Symp on the Use of Athymic (Nude) Mice in Cancer Research. New York: Gustav Fischer-Verlag 1977; 267-80.
24. Smith S, Stern A. The effect of aromatic CoA esters on fatty acid synthetase: biosynthesis of ω-phenyl fatty acids. Arch Biochem Biophys 1983; 222: 259-65.
25. Vamecq J, Vallee L, Fontaine M, et al. Preliminary studies about novel strategies to revers chemoresistance to adriamycin regarding glutathion metabolism, peroxisomal and extraperoxisomal hydroperoxide and valproic acid metabolic pathways. Biol Cell 1993; 77: 17-26.
26. Sidell N, Wada R, Han G, et al. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int J Cancer 1995; 60: 507-14.
27. Boffa LC, Mariani MR, Parker MI. Selective hypermethylation of transcribed nucleosomal DNA by sodium butyrate. Exp Cell Res 1994; 218: 420-3.